Upsher-Smith buys UK's Proximagen for £223m plus CVR
This article was originally published in Scrip
Executive Summary
Upsher-Smith Laboratories of the US is to buy the UK firm Proximagen for £223 million plus a potential £134 million through contingent value rights (CVRs) based on the success of two drugs in its pipeline.
You may also be interested in...
Harnessing AI For Drug Development – UK's BenevolentAI And MRCT Link
The hope artificial intelligence can revolutionize current drug discovery methods will be tested in a new collaboration between UK-based BenevolentAI and the medical research charity MRC Technology.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.